Letrozole

Generic Name
Letrozole
Brand Names
Femara, Kisqali Femara Co-pack
Drug Type
Small Molecule
Chemical Formula
C17H11N5
CAS Number
112809-51-5
Unique Ingredient Identifier
7LKK855W8I
Background

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication

Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.

Associated Conditions
Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-
Clinical Trials
Related News

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

First Posted Date
2017-03-30
Last Posted Date
2021-10-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
502
Registration Number
NCT03096847
Locations
🇩🇪

Novartis Investigative Site, Wuerzburg, Germany

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

First Posted Date
2017-02-23
Last Posted Date
2019-04-22
Lead Sponsor
University of Chicago
Registration Number
NCT03058939
Locations
🇳🇬

Lagos State University College of Medicine, Ikeja, Lagos State, Nigeria

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

First Posted Date
2017-02-17
Last Posted Date
2024-12-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
379
Registration Number
NCT03056755
Locations
🇺🇸

Kaiser Permanente Medical Group, Anaheim, California, United States

🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

and more 23 locations

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3
Terminated
Conditions
Breast Cancer
Interventions
Drug: Ribociclib
Drug: letrozole
First Posted Date
2017-02-10
Last Posted Date
2020-05-28
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
8
Registration Number
NCT03050398
Locations
🇺🇸

PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States

🇺🇸

Arizona Oncology Associates PC HAL, Sedona, Arizona, United States

🇺🇸

Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States

and more 3 locations

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Phase 3
Recruiting
Conditions
Infertility
Interventions
Drug: Tamoxifen
Drug: Letrozole
First Posted Date
2017-01-05
Last Posted Date
2024-05-08
Lead Sponsor
University of California, San Francisco
Target Recruit Count
144
Registration Number
NCT03011684
Locations
🇺🇸

University of California at San Francisco, San Francisco, California, United States

Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome

First Posted Date
2017-01-04
Last Posted Date
2022-05-09
Lead Sponsor
Assiut University
Target Recruit Count
150
Registration Number
NCT03009838
Locations
🇪🇬

Assiut University, Assiut, Egypt

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

First Posted Date
2017-01-02
Last Posted Date
2024-03-20
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
55
Registration Number
NCT03007979
Locations
🇺🇸

University of Nebraska, Lincoln, Nebraska, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

First Posted Date
2017-01-02
Last Posted Date
2024-12-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
90
Registration Number
NCT03008408
Locations
🇺🇸

Lyndon Baines Johnson General Hospital, Houston, Texas, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

First Posted Date
2016-12-30
Last Posted Date
2024-12-20
Lead Sponsor
Genentech, Inc.
Target Recruit Count
200
Registration Number
NCT03006172
Locations
🇺🇸

Massachusetts General Hospital., Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 10 locations

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

First Posted Date
2016-11-08
Last Posted Date
2020-09-02
Lead Sponsor
Lund University Hospital
Target Recruit Count
126
Registration Number
NCT02958852
Locations
🇸🇪

Lund University Hospital, Department of Oncology, Lund, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy